Class A Common Stock

Class A Common Stock

Shares of Class B Common Stock were converted at a 1:1 ratio for a share of Class A Common Stock at the election of the Reporting Person.

The shares are held by The AF Living Trust UTA dated 9/4/19 for which the Reporting Person serves as the trustee.

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 6, 2025.

This sale price represents the weighted average sale price of the shares sold ranging from $242.18 to $243.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $243.54 to $244.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $244.68 to $245.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $245.70 to $246.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $246.76 to $247.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $247.76 to $248.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

This sale price represents the weighted average sale price of the shares sold ranging from $248.78 to $249.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Certain of these securities are represented by restricted stock units.

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.


On August 1, 2024, the Reporting Person was granted restricted stock units ("RSUs") for 3,633.412 shares of KLA common stock. On August 1, 2025, twenty-five percent (25%) of the RSUs vested. Pursuant to the terms of the grant, shares of KLA common stock were automatically withheld at vesting to cover required tax withholding. The fair market value of KLA common stock used for purposes of calculating the number of shares to be withheld was the closing price of KLA common stock as reported on July 31, 2025.

The number of shares of KLA common stock includes 16,160.912 shares issuable upon vesting of RSUs.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Bren D. Higgins


Ordinary Shares

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.13 to $15.31, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Restricted share units were granted on August 1, 2024, with 12,827 vested on August 1, 2025, 12,827 vesting on each of August 1, 2026 and August 1, 2027, and 12,830 vesting on August 1, 2028.

Executive Vice President, Chief Human Resources Officer.

/s/ Dov Bergwerk as attorney-in-fact for Placid Jover


Vested shares under the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees settle for Ordinary Shares, nominal value $0.000304635 per share, on a 1:1 basis on the first business day of the month on which the NASDAQ Stock Market is open for business following the earlier of (i) the date that is 6 months after the reporting person's separation from service and (ii) the date that is 30 days after the reporting person's death.

Includes restricted share units credited to the participant's account by the Company pursuant to the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees (the "Plan") accrual formula, net of the units acquired pursuant to the participant's contribution under the Plan.

/s/ Carl A. Hess by Lina Vanessa Jaramillo, Attorney-in-Fact (power of attorney previously filed)


The 56,737 shares were sold through a number of separate trades, with sales price ranging from $21.80 to $21.87, and a weighted average sales price of $21.84.  The reporting person undertakes to provide, upon request by the Staff of the Securities and Exchange Commission, the issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The 7,015 shares were sold through a number of separate trades, with sales price ranging from $21.80 to $21.81, and a weighted average sales price of $21.80.  The reporting person undertakes to provide, upon request by the Staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

/s/Philip R. Martens, by Laura Lynn Church, Attorney-in-Fact


Reflects withholding of shares by the Company to cover tax withholding obligations on the vesting of restricted stock awards under the Company's Second Amended and Restated 2009 Equity Incentive Plan.

The amount of securities owned following the reported transaction reflects direct ownership of all shares of common stock, including restricted shares.

Lee N. Davis, as attorney-in-fact under Power of Attorney dated June 20, 2024


Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.

Represents the weighted average sale price of the shares sold ranging from $1.045 to $1.075 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.


The reported sale was effected pursuant to a Rule 10b5-1(c) trading plan adopted on February 10, 2025.

Represents (i) 39,859 shares or units of restricted stock, of which 5,737 are vested, (ii) 48,973 shares of Common Stock underlying PSUs, all of which are vested, and (iii) 3,719 shares of Common Stock purchased under the Issuer's Employee Stock Purchase Plan.


/s/ Julie J. Gebauer by Lina Vanessa Jaramillo, Attorney-in-Fact (power of attorney previously filed)


By: /s/ Daniel M. Bauer, as attorney-in-fact


Represents the weighted average sale price of the shares sold ranging from $1.04 to $1.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.


Ordinary Shares

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

Restricted share units were granted on August 1, 2022, with 52,742 vested on each of August 1, 2023, August 1, 2024 and August 1, 2025, and 52,744 vesting on August 1, 2026.

Executive Vice President, Global R&D and Chief Medical Officer

/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes


Received pursuant to Issuer's Directors' Stock Award Plan for service as a director - exempt transaction under Rule 16b-3 (d).

N/A.

/s/ Andres C. Ferrero , Attorney-in-Fact


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 23,377 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

These shares of common stock are jointly owned by the reporting person and his spouse.


Represents shares held by the Irrevocable Trust of Rose Dempsey, of which the reporting person has sole voting and dispositive power


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,069 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.


Grant of of restricted common stock (the "Shares") pursuant to Issuer's 2020 Equity Incentive Plan. Such Shares were granted as part of Reporting Person's compensation for services as a non-employee director of Issuer for the period August 1, 2025 through July 31, 2026.

The Shares vest in four equal quarterly increments on October 31, 2025, January 31, 2026, April 30, 2026, and July 31, 2026. The last quarter of unvested shares will automatically vest as of the annual meeting of stockholders if Reporting Person either is not re-elected or is not nominated for re-election, and the annual meeting occurs before the final vesting of the grant.

Shares are held by a trust, of which the Reporting Person disclaims beneficial ownership of Shares held by the trust except to the extent of their pecuniary interest therein.


Vested shares under the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees settle for Ordinary Shares, nominal value $0.000304635 per share, on a 1:1 basis on the first business day of the month on which the NASDAQ Stock Market is open for business following the earlier of (i) the date that is 6 months after the reporting person's separation from service and (ii) the date that is 30 days after the reporting person's death.

Includes restricted share units credited to the participant's account by the Company pursuant to the Willis Towers Watson Non-Qualified Stable Value Excess Plan for U.S. Employees (the "Plan") accrual formula, net of the units acquired pursuant to the participant's contribution under the Plan.

/s/ Andrew Krasner by Lina Vanessa Jaramillo, Attorney-in-Fact (power of attorney previously filed)


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 18,341 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 16,086 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 6,690 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

These shares of common stock are managed by Armorica Partners, LLC (formerly Armori Capital Management, LLC) ("Armorica Partners"). Mr. Forterre is the managing director and sole shareholder of Armorica Partners and has voting and dispositive control over the shares held by Armorica Partners. Mr. Forterre disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.


Adjusted to correct beneficial ownership prior to the reported transactions.

Represents shares of restricted stock awarded pursuant to a restated stock agreement, which vests on November 1, 2025.

Represents shares held by The Mark X DiSanto Investment Trust, of which Mr. DiSanto is trustee and as to which Mr. DiSanto has sole voting dispositive power.

Represents shares held by other trusts, of which Mr. DiSanto is trustee and as to which Mr. DiSanto has sole voting dispositive power.


Non-Qualified Stock Option (right to buy)

Common Stock

Option vested in three equal annual tranches commencing December 14, 2021.

/s/ R. Andrew Massey for Renee L. Campbell


Grant of restricted common stock (the "Shares") pursuant to Issuer's 2020 Equity Incentive Plan. Such Shares were granted as part of Reporting Person's compensation for services as a non-employee director of Issuer for the period August 1, 2025 through July 31, 2026.


Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,190 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

The shares of common stock are held directly by Concord International, Inc. The reporting person is a controlling director of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

This disposition represents shares withheld to satisfy tax withholding obligations on the restricted stock units that vested on August 4, 2025, and are reported herein.

Each restricted stock unit represents a contingent right to receive one share of Cognex Corporation common stock.

The restricted stock units vest approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date (August 4, 2022), respectively.


Common Stock

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.42 to $359.145, inclusive. The reporting person undertakes to provide to Valmont Industries, Inc., any security holder of Valmont Industries, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

Options vested in three equal annual tranches commencing December 14, 2021.

/s/ R. Andrew Massey for Timothy P. Francis


The Shares vest in four equal quarterly increments on October 31, 2025, January 31, 2026, April 30, 2026, and July 31, 2026. The last quarter of unvested shares will automatically vest as of the annual meeting of stockholders if Reporting Person either is not re-elected or is not nominated for re-election, and the annual meeting occurs before the final vesting of the grant.

Shares are held by a trust, of which the Reporting Person is trustee. Reporting Person disclaims beneficial ownership of Shares held by the trust except to the extent of their pecuniary interest therein.


Represents shares of common stock granted to the reporting person pursuant to his election under the Lands' End, Inc. Director Compensation Policy to receive a portion of the fees that would otherwise be payable to him in cash, in the form of shares of the issuer's common stock. Such shares were issued under the Lands' End, Inc. Amended and Restated 2017 Stock Plan.

/s/ Peter L. Gray, as Attorney-in-Fact for Robert Galvin


/s/ Peter L. Gray, as Attorney-in-Fact for Gordon Hartogensis


/s/ Richard C. Elias (by Mauro Premutico as power of attorney)


Represents shares of common stock granted to the reporting person pursuant to her election under the Lands' End, Inc. Director Compensation Policy to receive a portion of the fees that would otherwise be payable to her in cash, in the form of shares of the issuer's common stock. Such shares were issued under the Lands' End, Inc. Amended and Restated 2017 Stock Plan.

/s/ Peter L. Gray, as Attorney-in-Fact for Alicia Uhlman Parker


The Common Shares of Beneficial Interest, par value $0.001 per share ("Common Shares") of Overland Advantage (the "Issuer") reported herein are held directly by and beneficially owned by Platinum Falcon B 2018 RSC Limited ("Platinum Falcon").  Platinum International Investment Holdings RSC Limited ("Platinum Holdings") is the sole owner of Platinum Falcon, and Abu Dhabi Investment Authority ("ADIA" and, together with Platinum Falcon and Platinum Holdings, the "Reporting Persons") is the sole owner of Platinum Holdings. Therefore, Platinum Holdings and ADIA may also be deemed to beneficially own the Common Shares reported herein.


On July 8, 2025, Infinite Acquisitions delivered 7,969,309 shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock") of Falcon's Beyond Global, Inc. (the "Issuer")  pursuant to obligations underlying certain redemption agreements entered into with former equityholders of Infinite Acquisitions prior to the Business Combination described in the Registration Statement on Form S-4 (File No. 333-269778) (the "Registration Statement"). The arrangement obligates Infinite Acquisitions to deliver 8,433,392 shares of Class A Common Stock which may be acquired upon redemption by Infinite Acquisitions of an equal number of Common Units at certain redemption dates over a four-year period beginning following the closing of the Business Combination. In lieu of delivering Class A Common Stock, Infinite Acquisitions may elect to deliver an equivalent number of Common Units and Class B Common Stock.

(Continued from footnote 1) This Form 4/A is being filed to correct the Transaction Date reported in the third line of Table I of the Form 4 originally filed on July 8, 2025, which erroneously listed the Transaction Date as July 3, 2025.

Includes 400,000 shares of Class A Common Stock that are subject to earnout (the "Class A Earnout Shares") that are being held in an escrow account for the benefit of Infinite Acquisitions. The Class A Earnout Shares will be released to Infinite Acquisitions, if at all, upon the satisfaction of certain milestones described in the Registration Statement. Infinite Acquisitions's right to receive the Class A Earnout Shares upon satisfaction of the earnout conditions became fixed and irrevocable effective as of October 6, 2023. Once the Class A Earnout Shares are earned, released and delivered from escrow to Infinite Acquisitions, such shares shall be subject to an additional 1-year lock-up pursuant to an agreement between Infinite Acquisitions and the Issuer.

Represents securities held by Infinite Acquisitions. Infinite Acquisitions is controlled by its manager, Erudite Cria, Inc. ("Infinite Manager"). Investment and voting decisions at Infinite Manager with respect to the securities held by Infinite Acquisitions are made by the board of directors of Infinite Manager. Each director has one vote on all matters presented to the board of Infinite Manager, except that the chairman of the board of directors, Lucas Demerau, has two votes on all matters presented to the board of Infinite Manager. Therefore, no individual director of Infinite Manager is the beneficial owner, for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of the securities held by Infinite Acquisitions. Each of Infinite Manager and the directors of Infinite Manager disclaim beneficial ownership over such securities except to the extent of their individual pecuniary interest therein.


Common Stock, $.25 Par Value

Shares credited to the reporting person's account under The Coca-Cola Company 401(k) Plan, as of August 4, 2025.

Each hypothetical share is equal to one share of common stock of The Coca-Cola Company.

There is no data applicable with respect to the hypothetical shares.

As of August 4, 2025.


Common Stock


Included in this total are 8,353 shares held outright in Mr. Lyon's name and 8,593 shares held in Mr. Lyon's name in a brokerage account.


Includes shares acquired through dividend reinvestment plan


Includes Restricted Stock Awards totaling 46,382.731 shares

Jacob Burkett (Confirming Statement on File)


Includes Restricted Stock Awards totaling 25,389.389 shares


Includes Restricted Stock Awards totaling 29,826.334 shares


Includes Restricted Stock Awards totaling 12,869.314 shares.


Includes Restricted Stock Awards totaling 42,605.199 shares


Includes Restricted Stock Awards totaling 10,783.861 shares


Common Stock

Includes Restricted Stock Awards totaling 63,328.111 shares.

Each share of phantom stock is the economic equivalent of one share of FRME common stock. The shares of phantom stock will be settled in cash or shares of FRME common stock, at the reporting person's election, upon separation from First Merchants.


Common Stock

Includes Restricted Stock Awards totaling 21,442.059 shares


FS Credit Real Estate Income Trust, Inc.


/s/ Victor L. Cangelosi, pursuant to power of attorney


Restricted Stock Units (Performance Based Vesting)

Common Stock

Common Stock

Each restricted stock unit represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date

The performance based RSUs will vest based on achievement of identified performance measures for fiscal year 2026, with additional time-based vesting in equal 25% installments on June 30, 2027, 2028 and 2029, assuming the Reporting Person remains continuously employed on the vesting dates. The amount reported represents the amount of shares payable at maximum performance; the Reporting Person could earn 0 - 50% of the amount reported depending on the level of performance achieved

This award was granted 10-27-22. 443 restricted stock units plus an additional 38 dividend equivalent units subject to the award vested 06-30-25. 443 restricted units and associated dividend equivalents are scheduled to vest 6-30-26, assuming continued employment through applicable vesting date.


Common Stock

Forfeiture of restricted stock grants.

2016 Grant = $21.60, 2017 Grant = $26.17, 2018 Grant = $49.50 and 2019 Grant = $59.70.

All stock appreciation rights have vested.

The stock appreciation rights expire as follows: 2/1/2026 for the 2016 grant, 2/6/2027 for the 2017 grant, 2/5/2028 for the 2018 grant and 2/4/2029 for the 2019 grant.


Held in F&M Bank Corp. Employee Stock Ownership Plan


Represents the sale of shares in open market.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.30 to $45.09, inclusive. The reporting person undertakes to provide to TTM Technologies, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.


GINA MARIE BOOR FOR R. JOSEPH LANDY UNDER POWER OF ATTORNEY DATED 08/22/2022


/s/ Robert Stieger, by POA from Reporting Person


The shares reported relate to restricted stock units awarded to the reporting person and are subject to specified vesting and settlement provisions.

Includes 9,707.230 restricted stock units awarded to the reporting person that are subject to specified vesting and settlement provisions.


Held by an irrevocable trust for benefit of his spouse and descendants (of which the reporting person's spouse, adult daughter and unrelated third person are trustees).


The sale reported on this Form 4 occured automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.


Represents shares of stock granted in lieu of quarterly cash payment for services rendered as a member of the Company's Board of Directors.

Thomas C. Burke, Attny in Fact for Mr. Klein


common stock

Represents the conversion, upon vesting, of restricted stock units into common stock.

Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on August 1, 2025 of the restricted stock units awarded to the reporting person on August 1, 2023. The award includes a provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the award.

Each Restricted Stock Unit represents the right to receive, following vesting, one share of Forrester Research, Inc. common stock.

On August 1, 2023, the reporting person was granted 3,702 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.

This Form 4A is being filed to correct the share price in the second row of Table I, Section 4 which was originally reported as $12.94.  The correct price is $10.94.  It is also filed to correct the number of derivative securities beneficially owned following the reported transaction in Table II, Section 9.  The number of derivaties was originally reported as 0.  The correct number of derivaties is 1,850.

Maite Garcia, attorney-in-fact for Scott Chouinard


Thomas C. Burke, Attny in Fact for Molly Langenstein


Institutional Investment Strategy Fund - Investor Class Shar


Includes dividends issued periodically under the Issuer's Dividend Reinvestment Plan.

Kathleen E. Cook, Attorney in Fact, Pursuant to Power of Attorney dated 6/25/2025


common stock

common stock

Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on August 1, 2025 of the restricted stock units awarded to the reporting person on August 2, 2021 and August 1, 2023. The awards include a provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the awards.

On August 2, 2021, the reporting person was granted 550 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on August 1, 2022, August 1, 2023, August 1, 2024 and August 1, 2025.

On August 1, 2023, the reporting person was granted 1234 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on August 1, 2024, August 1, 2025, August 1, 2026 and August 1, 2027.

Maite Garcia, attorney-in-fact for Andrew Cox


Humana Common

Humana Common

Right to receive one share per restricted stock unit pursuant to the Company's 2019 Amended & Restated Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3).

Restricted stock units granted to reporting person on 8/1/2022, 33% of the award is vesting on 8/1/23, 8/1/24, and 8/1/25.

Restricted stock units granted to reporting person on 2/24/2023, 33% of the award is vesting on 12/15/23, 12/15/24, and 12/15/25.

Includes 1,203 restricted stock units representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.

Shares disposed of represent payment for tax liability on restricted stock vesting 8/1/25. No value was received in return.


15,000 shares of Bankwell Financial Group, Inc. stock granted pursuant to the 2022 Bankwell Financial Group, Inc. Stock Plan. These shares are performance restricted stock with a three year cliff vesting on February 7, 2028 if the performance goals are achieved.

10,000 shares of Bankwell Financial Group, Inc. stock granted pursuant to the 2022 Bankwell Financial Group, Inc. Stock Plan. The shares are restricted stock that will vest in three substantially equal annual installments, with the first installment vested on July 1, 2024 and the second and third installments to vest on each annual anniversary of the vesting date thereafter. As of the filing date, 6,666 shares have vested.

/s/ Angelo G. Fusaro, Attorney-in-Fact for Ryan J. Hildebrand


The sale reported in this Form 4 was effected by a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024.

Represents 210,840.720 vested restricted stock units and 91,314 shares of Common Stock.

Linea K. Michael, Attorney in Fact for Marita Zuraitis


Includes shares of common stock acquired through dividend reinvestment.


common stock

common stock

common stock

Represents the conversion, upon vesting, of restricted stock units into common stock.

Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on August 1, 2025 of the restricted stock units awarded to the reporting person on August 2, 2021, August 1, 2023 and August 1, 2024. The awards include a
provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the awards.

Each Restricted Stock Unit represents the right to receive, following vesting, one share of Forrester Research, Inc. common stock.

On August 2, 2021, the reporting person was granted 705 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on August 1, 2022, August 1, 2023, August 1, 2024 and August 1, 2025.

On August 1, 2023, the reporting person was granted 2,536 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.

On August 1, 2024, the reporting person was granted 7,882 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.

Maite Garcia, attorney-in-fact for Michael Facemire


common stock

Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on August 1, 2025 of the restricted stock units awarded to the reporting person on August 1, 2023. The award includes a provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the award.

On August 1, 2023, the reporting person was granted 3,702 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments beginning on the first anniversary of the grant date.


Represents shares of common stock, par value $0.0001 per share ("Common Stock"), underlying restricted stock units ("RSUs") granted to the reporting person on August 1, 2025 (the "August 2025 Grant Date") pursuant to the Issuer's 2023 Incentive Plan. One-Third (1/3) of the RSUs shall vest, and an equal number of shares of Common Stock will be deliverable to the reporting person, on each of the first three anniversaries of the August 2025 Grant Date, subject to continued service through each such vesting date.

Includes 144,000 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on November 11, 2024 (the "Grant Date") pursuant to the Issuer's 2023 Incentive Plan. One-Third (1/3) of the RSUs shall vest, and an equal number of shares of Common Stock will be deliverable to the reporting person, on each of the first three anniversaries of October 7, 2024, subject to continued service through each such vesting date.

/s/ Bill Roeschlein, as attorney-in-fact


Includes 28,985 shares of Common Stock underlying RSUs granted to the reporting person on August 11, 2023 (the "August 2023 Grant Date") and 71,274 shares of Common Stock underlying RSUs granted to the reporting person on September 16, 2024 (the "September 2024 Grant Date"), in each case, pursuant to the Issuer's 2023 Incentive Plan.

(Continued from Footnote 2) One-Third (1/3) of the RSUs initially granted to the reporting person on August 11, 2023 vested and were delivered to the reporting person on August 11, 2024, the first anniversary of the August 2023 Grant Date, and one-third of the RSUs subject to the grant shall vest and be deliverable to the reporting person on each of the second and third anniversaries of the August 2023 Grant Date, subject to continued service through each such vesting date. One-Third (1/3) of the RSUs granted to the reporting person on September 16, 2024 shall vest, and an equal number of shares of Common Stock will be deliverable to the reporting person, on each of the first three anniversaries of the September 2024 Grant Date, subject to continued service through each such vesting date.

The reporting person undertakes to provide to Tigo Energy, Inc., any security holder of Tigo Energy, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price, with respect to all transactions reported on this Form 4.


Includes 50,724 shares of Common Stock underlying RSUs granted to the reporting person on August 11, 2023 (the "August 2023 Grant Date") and 177,776 shares of Common Stock underlying RSUs granted to the reporting person on September 16, 2024 (the "September 2024 Grant Date"), in each case, pursuant to the Issuer's 2023 Incentive Plan.


Includes 28,985 shares of Common Stock underlying RSUs granted to the reporting person on August 11, 2023 (the "August 2023 Grant Date") and 71,396 shares of Common Stock underlying RSUs granted to the reporting person on September 16, 2024 (the "September 2024 Grant Date"), in each case, pursuant to the Issuer's 2023 Incentive Plan.


Includes 115,942 shares of Common Stock underlying RSUs granted to the reporting person on August 11, 2023 (the "August 2023 Grant Date") and 333,330 shares of Common Stock underlying RSUs granted to the reporting person on September 16, 2024 (the "September 2024 Grant Date"), in each case, pursuant to the Issuer's 2023 Incentive Plan.


common stock

Represents shares withheld by the Issuer to satisfy tax withholding obligations upon the vesting on August 1, 2025 of the restricted stock units awarded to the reporting person on August 2, 2021. The award includes a provision for the withholding of shares by the Issuer to satisfy withholding taxes due as a result of the vesting of the award.

On August 2, 2021, the reporting person was granted 6,059 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on August 1, 2022, August 1, 2023, August 1, 2024 and August 1, 2025.

Maite Garcia, attorney-in-fact for Ryan Darrah


common stock

Represents the conversion, upon vesting, of restricted stock units into common stock.

On August 2, 2021, the reporting person was granted 3,305 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on August 1, 2022, August 1, 2023, August 1, 2024 and August 1, 2025.

Maite Garcia, attorney-in-fact for Sharyn Leaver


common stock

Each Restricted Stock Unit represents the right to receive, following vesting, one share of Forrester Research, Inc. common stock.

On August 2, 2021, the reporting person was granted 8,814 Restricted Stock Units that vest and convert into common stock in four equal and consecutive installments on August 1, 2022, August 1, 2023, August 1, 2024 and August 1, 2025.

Maite Garcia, attorney-in-fact for Carrie Johnson


Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $130,000 by a 30-day trailing average stock price.


Performance based restricted stock shares granted pursuant to the Brookline Bancorp, Inc. 2021 Stock Option and Incentive Plan.  The shares vest on the third anniversary of the date of grant based on certain performance based metrics.

Includes shares of restricted stock granted pursuant to the Brookline Bancorp, Inc. 2021 Stock Option and Incentive Plan.

William C. Tsonos, by Marissa S. Martin, POA


Paul A. Perrault, by Marissa S. Martin, P.O.A.


Remarketable Variable Rate MuniFund Term Preferred Shares

In connection with the reorganization of PIMCO Municipal Income Fund III and PIMCO Municipal Income Fund (the "Target Funds") into the Issuer, 443 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Target Funds beneficially owned by Wells Fargo Municipal Capital Strategies, LLC ("Capital Strategies") were exchanged for an equal number of RVMTP Shares of the Issuer in a cashless transaction. The 443 RVMTP shares reported as acquired in Table I represent shares beneficially owned by Capital Strategies.  Capital Strategies is a wholly owned subsidiary of Wells Fargo & Company ("Wells Fargo").

The 555 RVMTP Shares were previously acquired by Capital Strategies as reported in the Form 3 filing filed by Wells Fargo and Capital Strategies with the United States Securities and Exchange Commission on September 20, 2023.

This statement is jointly filed by Wells Fargo and Capital Strategies.  Wells Fargo holds an indirect interest in the securities listed in Table I by virtue of its indirect ownership of its subsidiary Capital Strategies.

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Exhibits Index
Exhibit 99.1 - Joint Filing Agreement
Exhibit 99.2 - Joint Filer Information


ResMed Common Stock

The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

Represents date options first become exercisable. Options vest 1/3 per year.

Brett Sandercock, Chief Financial Officer


Includes 2,261 unvested restricted stock units for which the reporting person does not have voting rights or receive dividends until vesting and shares are issued: 753 vesting 2/1/2026; 754 vesting 2/1/2027, and 754 vesting 2/1/2028.


Mark J. Meiklejohn, by Marissa S. Martin, P.O.A.


This figure does not include 99,970 shares held directly by Mr. Stahl.

For each indirect account, Mr. Stahl disclaims beneficial ownership except to the extent of his pecuniary interest, if any.


In connection with the reorganization of the Issuer into PIMCO Municipal Income Fund II ("PML"), 239 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer beneficially owned by Wells Fargo Municipal Capital Strategies, LLC ("Capital Strategies") were exchanged for an equal number of RVMTP Shares of PML in a cashless transaction. The 239 shares reported as disposed of in Table I represent shares that were beneficially owned by Capital Strategies. Capital Strategies is a wholly owned subsidiary of Wells Fargo & Company ("Wells Fargo").


Michael W. McCurdy, by Marissa S. Martin, P.O.A.


Represents shares withheld by the Issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.


In connection with the reorganization of the Issuer into PIMCO Municipal Income Fund II ("PML"), 182 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer indirectly beneficially owned by JPMorgan Chase Bank, National Association ("JPMCB") were exchanged for an equal number of RVMTP Shares of PML in a cashless transaction. The 182 RVMTP shares reported as disposed of in Table I represent shares that were indirectly beneficially owned by JPMCB.

/s/  Charles Giffin, Charles Giffin, Authorized Signatory


Acquisition of additional deferred stock units upon deemed reinvestment of dividend equivalents, in a transaction exempt under Rule 16b-3(d).


The reported sale of 500 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2024.

/s/ Hope Katz, Attorney-in-fact for John McCartney


In connection with the reorganization of the Issuer into PIMCO Municipal Income Fund II ("PML"), 204 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer beneficially owned by Wells Fargo Municipal Capital Strategies, LLC ("Capital Strategies") were exchanged for an equal number of RVMTP Shares of PML in a cashless transaction. The 204 shares reported as disposed of in Table I represent shares that were beneficially owned by Capital Strategies. Capital Strategies is a wholly owned subsidiary of Wells Fargo & Company ("Wells Fargo").


Michael P. Goldrick, by Marissa S. Martin, POA


Kaushik Ghoshal and Jayati Ghoshal Family Trust

Mr. Ghoshal is no longer subject to reporting due to termination as of August 1, 2025.

Kaushik Ghoshal, Chief Commercial Officer, SaaS business


Represents the annual grant of a stock award to the Reporting Person as a non-employee director of the Issuer at the Issuer's first quarterly board meeting following the Annual Meeting of Stockholders. The number of shares awarded is determined by dividing $130,000 by a 30-day trailing average stock price.


Performance based restricted stock shares granted pursuant to the Brookline Bancorp, Inc. 2021 Stock Option and Incentive Plan.  The shares vest on the third anniversary of the date of grant based on certain performance based metrics.

Includes shares of restricted stock granted pursuant to the Brookline Bancorp, Inc. 2021 Stock Option and Incentive Plan.

Darryl J. Fess, by Marissa S. Martin, P.O.A.


Common Stock

Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of MKS Inc.

These RSUs vest in three equal annual installments commencing on February 15, 2026, provided that if, in any vesting year, February 15th is not a business day, such vesting shall occur on the next business day.

/s/ M. Kathryn Rickards, attorney-in-fact


Common Stock

Common Stock

Represents the vesting and settlement of restricted stock units, which convert into common stock on a one-for-one basis.

The restricted stock units were granted to the reporting person under the Warrior Met Coal, Inc. 2017 Equity Incentive Plan, and vest in equal installments on each of the first three anniversaries of August 1, 2022, the date of grant.

The restricted stock units were granted to the reporting person under the Warrior Met Coal, Inc. 2017 Equity Incentive Plan, and vest in full on the first anniversary of April 23, 2025, the date of grant, and will be settled in shares of common stock upon the reporting person's termination of service as a director in accordance with the reporting person's irrevocable deferral election.


The reported sale of 400 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

/s/ Hope Katz, Attorney-in-fact for Hugh E. Sawyer


PIMCO CALIFORNIA MUNICIPAL INCOME FUND III

In connection with the reorganization of the Issuer into PIMCO California Municipal Income Fund ("PCQ"), 271 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer indirectly beneficially owned by JPMorgan Chase Bank, National Association ("JPMCB") were exchanged for an equal number of RVMTP Shares of PCQ in a cashless transaction. The 271 RVMTP shares reported as disposed of in Table I represent shares that were indirectly beneficially owned by JPMCB.

/s/ Charles Giffin, Charles Giffin, Authorized Signatory


Shares were surrendered to satisfy tax withholding obligations arising from the vesting of restricted stock - 3rd tranche vesting of Sign-on Bonus.

/s/ Lynn M. Floeter, attorney-in-fact for Derek S. Meyer


Carl M. Carlson, by Marissa S. Martin, P.O.A.


Common Stock

Sales at prices ranging from $136.79 per share to $137.78 per share.

Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.

Michael C. Majors, By /s/ Chris T. Moore, Attorney-in-fact


Common Stock

Common Stock

Common Stock

Common Stock

Purchases made with optional cash contribution pursuant to the RGC Resources, Inc. Dividend Reinvestment and Stock Purchase Plan.

Includes 84.058 shares purchased 08/01/2025 through dividends reinvested in the RGC Resources, Inc. Dividend Reinvestment and Stock Purchase Plan and 132.452 restricted shares purchased 08/01/2025 through dividends reinvested in the RGC Resources, Inc. Restricted Stock Plan.


Janytra M. Brooks, by Marissa S. Martin, POA


Kenneth R. Urmie, Deputy Corporate Secretary, for Tracy S. McCormick under Power of Attorney dated April 27, 2023


Includes 10.714 shares purchased 08/01/2025 through dividends reinvested in the RGC Resources, Inc. Dividend Reinvestment and Stock Purchase Plan.

/s/ Thomas Patrick Furcron by Lawrence T. Oliver, POA dated 06/02/2025


Phantom Stock ONB Executive Deferred Compensation Plan

Common Stock

Shares of phantom stock acquired under the Old National Bancorp Executive Deferred Compensation Plan (the "Plan") represent shares of Old National Bancorp common stock on a 1-for-1 basis and are payable in cash upon distribution to the Reporting Person in accordance with the terms of the Plan.

/s/ Sharon K. Brantley, Paralegal, as Attorney-In-Fact for James A. Sandgren


PIMCO CALIFORNIA MUNICIPAL INCOME FUND II

In connection with the reorganization of the Issuer into PIMCO California Municipal Income Fund ("PCQ"), 292 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer beneficially owned by Wells Fargo Municipal Capital Strategies, LLC ("Capital Strategies") were exchanged for an equal number of RVMTP Shares of PCQ in a cashless transaction. The 292 shares reported as disposed of in Table I represent shares that were beneficially owned by Capital Strategies. Capital Strategies is a wholly owned subsidiary of Wells Fargo & Company ("Wells Fargo").

This statement is jointly filed by Wells Fargo and Capital Strategies.  Wells Fargo holds an indirect interest in the securities listed in Table I by virtue of its indirect ownership of its subsidiary Capital Strategies.

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.


In connection with the reorganization of PIMCO California Municipal Income Fund II ("PCK") and PIMCO California Municipal Income Fund III ("PZC", and together the "Target Funds") into the Issuer, 546 Series 2054-A remarketable variable rate munifund term preferred shares ("RVMTP Shares"), comprised of 275 RVMTP Shares issued by PCK and 271 RVMTP Shares issued by PZC, each of which was indirectly beneficially owned by JPMorgan Chase Bank, National Association ("JPMCB") were exchanged for an equal number of RVMTP Shares of the Issuer in a cashless transaction. The 546 RVMTP shares reported as acquired in Table I represent RVMTP Shares indirectly beneficially owned by JPMCB, of which, (a) 275 RVMTP Shares are held in a trust designated as the J.P. Morgan Taxable Putters/Taxable Drivers, Series 5059 Trust and

(Continued from footnote 1) (b) 271 RVMTP Shares are held in a trust designated as the J.P. Morgan Taxable Putters/Taxable Drivers, Series 5060 Trust. JPMCB, as a beneficiary of each of these trusts, and through its contractual rights, retains an indirect beneficial ownership in the RVMTP Shares.

In addition to the 546 RVMTP Shares reported in Table I above, 244 RVMTP Shares of the Issuer are held indirectly beneficially held by JPMCB in a trust designated as the J.P. Morgan Taxable Putters/Taxable Drivers, Series 5058 Trust as reported in the Form 4 filing filed by JPMCB with the United States Securities and Exchange Commission filed July 1, 2024.


Common Stock

Includes 12.728 shares purchased 08/01/2025 through dividends reinvested in the RGC Resources, Inc. Dividend Reinvestment and Stock Purchase Plan and 58.122 restricted shares purchased 08/01/2025 through dividends reinvested in the RGC Resources, Inc. Restricted Stock Plan.


Shares issued to reporting person pursuant to an election under the Restricted Stock Plan for Outside Directors of RGC Resources, Inc.

Includes 252.168 restricted stock shares purchased 08/01/2025 through dividends reinvested in the Restricted Stock Plan for Outside Directors of RGC Resources, Inc.

/s/ John B. Williamson, III by Lawrence T. Oliver, POA dated 02/05/2024


Includes 40.183 restricted stock shares purchased 08/01/2025 through dividends reinvested in the Restricted Stock Plan for Outside Directors of RGC Resources, Inc.

/s/ Elizabeth A. McClanahan by Lawrence T. Oliver, POA dated 02/05/2024


Includes 89.151 restricted stock shares purchased 08/01/2025 through dividends reinvested in the Restricted Stock Plan for Outside Directors of RGC Resources, Inc.

/s/ Thomas J. Crawford by Lawrence T. Oliver, POA dated 02/05/2024


In connection with the reorganization of the Issuer into PIMCO California Municipal Income Fund ("PCQ"), 275 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer indirectly beneficially owned by JPMorgan Chase Bank, National Association ("JPMCB") were exchanged for an equal number of RVMTP Shares of PCQ in a cashless transaction. The 275 RVMTP shares reported as disposed of in Table I represent shares that were indirectly beneficially owned by JPMCB.


Includes 64,782.705 shares owned directly by reporting person and includes 515.338 restricted shares purchased 08/01/2025 through dividends reinvested in the Restricted Stock Plan for Outside Directors of RGC Resources, Inc. Also includes 375.000 shares owned indirectly through UTMA for the reporting person's child.

/s/ Abney S. Boxley, III by Lawrence T. Oliver, POA dated 02/05/2024


Includes 167.350 restricted stock shares purchased 08/01/2025 through dividends reinvested in the Restricted Stock Plan for Outside Directors of RGC Resources, Inc.

/s/ Jacqueline L. Archer by Lawrence T. Oliver, POA dated 02/05/2024


Common Stock,  $0.01 par value per share

Represents award pursuant to 2023 Omnibus Incentive Plan; shares vest ratably over a three-year period beginning on August 1, 2025 and ending on the third anniversary thereof. Each restricted stock unit represents the right to receive one share of the Issuer's Common Stock upon vesting. These restricted stock units are subject to forfeiture and to limits on transferability until they vest.

Closing price on August 1, 2025.


Reporting person has 51,936.804 shares in a revocable trust for which she serves as trustee, which includes 485.772 restricted shares purchased 08/01/2025 through dividends reinvested in the Restricted Stock Plan for Outside Directors of RGC Resources, Inc. Also includes 8,700.303 shares previously owned by her spouse, which have been transferred to a revocable trust for which the spouse serves as trustee and which includes 90.776 shares purchased 08/01/2025 through dividends reinvested in the Dividend Reinvestment and Stock Purchase Plan for RGC Resources, Inc.

/s/ Nancy H. Agee by Lawrence T. Oliver, POA dated 02/05/2024


Award vests in three equal installments beginning on December 15, 2025 and annually thereafter during such periods of continued service as an Employee, Outside Director or Director Emeritus, as applicable.

/s/Ronald R. Schmalzle, by John M. McCaffery, Attorney-in-Fact


In connection with the reorganization of the Issuer into PIMCO Municipal Income Fund II ("PML"), 343 remarketable variable rate munifund term preferred shares (the "RVMTP Shares") of the Issuer indirectly beneficially owned by JPMorgan Chase Bank, National Association ("JPMCB") were exchanged for an equal number of RVMTP Shares of PML in a cashless transaction. The 343 RVMTP shares reported as disposed of in Table I represent shares that were indirectly beneficially owned by JPMCB.


On December 18, 2024, Horizon Kinetics Asset Management LLC (HKAM) filed an amendment to its Schedule 13D, in which it noted beneficial ownership of 3,578,173 shares and Murray Stahl's direct interest in 7,848 shares and his indirect interest in approximately 156,083 shares. The extent of HKAM's pecuniary interest in the shares beneficially owned is disclosed herein. Mr. Stahl does not exercise investment discretion with respect to the securities of the Issuer.


In connection with the reorganization of PIMCO Municipal Income Fund III ("PMX") and PIMCO Municipal Income Fund ("PMF", and together the "Target Funds") into the Issuer, 525 Series 2054-A remarketable variable rate munifund term preferred shares ("RVMTP Shares"), comprised of 343 RVMTP Shares issued by PMX and 182 RVMTP Shares issued by PMF, each of which was indirectly beneficially owned by JPMorgan Chase Bank, National Association ("JPMCB") were exchanged for an equal number of RVMTP Shares of the Issuer in a cashless transaction. The 525 RVMTP shares reported as acquired in Table I represent RVMTP Shares indirectly beneficially owned by JPMCB, of which, (a) 343 RVMTP Shares are held in a trust designated as the J.P. Morgan Taxable Putters/Taxable Drivers, Series 5064 Trust and

(Continued from footnote 1) (b) 182 RVMTP Shares are held in a trust designated as the J.P. Morgan Taxable Putters/Taxable Drivers, Series 5062 Trust. JPMCB, as a beneficiary of each of these trusts, and through its contractual rights, retains an indirect beneficial ownership in the RVMTP
Shares.

In addition to the 525 RVMTP Shares reported in Table I above, 687 RVMTP Shares of the Issuer are held indirectly beneficially held by JPMCB in a trust designated as the J.P. Morgan Taxable Putters/Taxable Drivers, Series 5063 Trust as reported in the Form 4 filing filed by JPMCB with the United States Securities and Exchange Commission filed July 3, 2024.


By Kisatchie Industries, LLC, for which Mr. Price serves as Manager.

Includes 16,500 shares previously reported as held in an estate that are now directly held as a result of settlement of the estate.

This transaction was executed in multiple trades at prices ranging from $59.87 to $60.51, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

/s/ Julia E. Callis, as Attorney-in-Fact


Common stock

Stock options granted under the 2014 Equity Incentive Plan vest in 25% increments on 12/31/18, 12/31/19, 12/31/20 and 12/31/21.

Matthew B. Kelpy, Attorney-in-fact for Susan Williamson Ross


Common Stock

Represents the purchase price for each share of Common Stock purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.

The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes.

The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation.

Represents the purchase price for each pre-funded warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.


Trustee of Martin Tuchman Revocable Trust

Martin Tuchman, by Edward Hogan, attorney-in-fact


The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $421.00 to $426.16.  The reporting person undertakes to provide to Chemed Corporation, any security holder of Chemed Corporation, or staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) of this Form 4.


Common Stock

Common Stock

Each restricted stock unit represents a contingent right to receive one share of Sonoco Products Company common stock.

The restricted stock units vest beginning one year from date of grant in three annual installments of 33%, 33%  and 34%.

The restricted stock units vest 3 years from date of grant.  Vested shares will be paid to the reporting person six months following retirement or termination of service.

By:Elizabeth R Kremer-Power of Attorney for Paul Joachimczyk


COMMON STOCK

COMMON STOCK

COMMON STOCK

Adjusted for 2/28/2023 two-for-one stock split

The options vest 25% at the date of each grant and then in three equal annual installments beginning on the 1 year anniversary of each grant.

/s/ Gregory Gaughan, By Power of Attorney


BLACKROCK CALIFORNIA MUNICIPAL INCOME TRUST


Common Stock

Common Stock

Common Stock

Common Stock

This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.

Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.


Common Stock

Common Stock


Common Stock

Common Stock

Common Stock


Common stock issued to the reporting Director in lieu of quarterly cash retainer payment.

William E. Matthews, V, CFO, pursuant to power of attorney


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Each stock option having an exercise price per share that is equal to or greater than the Closing Amount but less than $10.00 was cancelled and converted into the right to receive one CVR for each share subject to such option immediately prior to the Effective Time, except that if the milestone is achieved in respect of the CVR, the cash amount to be paid to such option holder will be an amount equal to (i) $10.00 minus (ii) the exercise price per share subject to such option, subject to applicable tax withholdings


By Atlas Venture Opportunity Fund I, L.P.

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

These shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XII, except to the extent of his pecuniary interest therein, if any.

The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock


Common Stock

The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date.

Multiple restricted share grants are included in this total.


Common Stock

Each restricted stock unit represents a right to receive one share of MTRN common stock.

Consists of restricted stock units granted on 03/01/2023, 03/01/2024, and 03/01/2025 that will vest in three substantially equal annual installments on the first three anniversaries of the grant date, and restricted stock units granted on 03/01/2025 that will vest in a single installment on 03/01/2028.

Expiration Date is the same as the Date Exercisable.

/s/Michelle R. Mekinda, as Attorney-In-Fact


Shares withheld to satisfy tax withholding obligations arising upon the vesting of restricted stock units in a transaction exempt under Rule 16b-3.


Common Stock

Holdings include shares acquired in dividend reinvestment transactions.

Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in one installment on 8/4/2025, the business day immediately following 8/3/2025. The Reporting Person's Form 4 filed on 8/4/2022 incorrectly reported that these restricted stock units vested and were to be distributed in three equal installments on 8/3/2023, 8/3/2024, and 8/3/2025.

/s/ Kelly E. W. Grez as Attorney-in-Fact for David Michael Williams


Common Stock

Includes shares acquired and dividends earned through July 8, 2025 in the Merck U.S. Savings Plan, a 401(k) plan.

These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 8/3/2023, 8/3/2024 and 8/3/2025 or, if such date was not a business day, the business day immediately thereafter.

/s/ Kelly Grez, as attorney-in-fact for Mr. Chirfi Guindo


The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $14.91 to $15.01, inclusive.  The reporting person undertakes to provide the SEC staff, Citizens Community Bancorp, Inc., or any security holder of Citizens Community Bancorp, Inc., upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

/s/ Rebecca L. Johnson, Attorney-in-fact


Ther price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $49.01 to $49.25 per share, inclusive. The reporting person shall provide to the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.

Includes shares acquired pursuant to the Issuer's Employee Stock Purchase Plan.  Such acquisitions are exempt under Rule 16-b3.

Reflects the total number of shares directly held by the reporting person following contributions of shares by the reporting person and the reporting person's spouse to the Foran 2012 Savings Trust and the Foran 2012 Security Trust, pursuant to the terms thereof.

The reporting person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of these shares. The reporting person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

Represents shares held of record by the Foran 2012 Savings Trust for which the reporting person's spouse is a trustee. Includes shares held by the trust following a contribution of shares by the reporting person to the trust, pursuant to the terms thereof.

Represents shares held of record by the Foran 2012 Security Trust for which the reporting person is the trustee. Includes shares held by the trust following a contribution of shares by the reporting person's spouse to the trust, pursuant to the terms thereof.

Represents shares held of record by Sage Resources, Ltd., which is a limited partnership owned by the reporting person's family, including the reporting person.

Represents shares held of record collectively by the LRF 2011 Non-GST Trust, WJF 2011 Non-GST Trust, JNF 2011 Non-GST Trust, SIF 2011 Non-GST Trust and MCF 2011 Non-GST Trust (collectively, the "2011 Non-GST Trusts").  The reporting person and his spouse, as settlors of each of the 2011 Non-GST Trusts, retain the power of substitution with respect to the property of the 2011 Non-GST Trusts.

Represents shares held of record collectively by the LRF 2020 Non-GST Trust, WJF 2020 Non-GST Trust, SIF 2020 Non-GST Trust and MCF 2020 Non-GST Trust (collectively, the "2020 Non-GST Trusts").  The reporting person and his spouse, as settlors of each of the 2020 Non-GST Trusts, retain the power of substitution with respect to the property of the 2020 Non-GST Trusts.

Represents shares held of record by the JWF 2023-2 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the NNF 2023-2 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the JWF 2024-1 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the NNF 2024-1 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the JWF 2024-2 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the NNF 2024-2 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the JWF 2025-1 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the NNF 2025-1 GRAT, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

/s/ Joseph Wm. Foran, by Cale L. Curtin as attorney-in-fact


Spouse is Trustee of the Emily J. Petrie Irrevocable GST Trust 2010

Spouse is Trustee of the Emily J. Petrie Irrevocable Trust - 2010

Spouse is Trustee of the Julia L. Petrie Irrevocable GST Trust 2010

Spouse is Trustee of the Julia L. Petrie Irrevocable Trust - 2010

Spouse is Trustee of The Petrie Grandchildren Trust

Includes 58,203 unvested restricted stock units for which the reporting person does not have voting rights or receive dividends until vested and shares are issued: 29,807 vesting 2/1/2026; 20,736 vesting 2/1/2027, and 7,660 vesting 2/1/2028.


These shares of restricted stock will vest on May 8, 2026.

/s/ Jerome D. Hall, Jr. by Theodore R. Moore, as Attorney-in-fact


The reporting person surrendered 32 shares to Keysight to satisfy tax liability on the release of restricted shares in accordance with Rule 16b-3.

Jeffrey K. Li, Attorney-in-fact for Lisa M. Poole


Number of shares of common stock withheld to satisfy the reporting person's tax withholding obligations upon vesting of a previously reported restricted stock unit award.


Common Stock

Common Stock

The reporting person entered into an Option Purchase Agreement dated January 9, 2024, where Hampton Growth Resources, LLC ("Hampton") acquired the option and right to purchase 1,400,000 shares of the Issuer's common stock. On July 28, 2025, the reporting person, the Issuer and Hampton entered into an Option Assignment Agreement and the sale of the option was consummated on August 1, 2025.

On July 31, 2025, Hampton provided an exercise notice to the reporting person which was consummated on August 1, 2025.


The shares were acquired from the issuer's treasury in satisfaction of outstanding liabilities, debt financing, accrued interest, and bonuses in lieu of cash, at a deemed fair market value of $1.31 per share (based on the average closing price over the prior 60 trading days).

Following the acquisition of 730,059 shares, based on 102,399 shares held prior to the transaction.


Granted under an equity incentive plan of Ares Management Corporation. Each restricted unit represents the right to receive one share of Class A Common Stock upon vesting. The restrictions on such units are scheduled to lapse on the first anniversary of the grant date.

Includes 1,166 restricted units granted under an equity incentive plan of Ares Management Corporation. Each restricted unit represents the right to receive one share of Class A Common Stock upon vesting. The restricted units vest in installments in accordance with the applicable restricted unit award agreement.

/s/ Anton Feingold, by power of attorney


Non-Voting Ordinary Shares, No Par Value

The reported sales are between the Issuer and College Top Holdings, Inc., as part of the Issuer's share repurchase program and are intended to keep the Reporting Persons' ownership of Taboola's outstanding shares from reaching 25% or more. See Exhibit 99.1 for more information.

See Exhibit 99.1.


The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations.

/s/ Meredith Prithviraj by Power of Attorney for Kabir Nath


Held by Pardeep Nijhawan Medicine Professional Corporation

Held by The New Nijhawan Family Trust 2015

Held by The Digestive Health Clinic Inc.

Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan


See Exhibit 99.1.


The restricted stock units (the "RSUs") granted to the Reporting Person on July 31, 2025 (the "grant date") as referenced herein, are issued pursuant to that October 31, 2024 Corporate Action, Change of Control, and Extraordinary Performance Agreement ( the "Extraordinary Performance Agreement") instituted and adopted by the board of directors of the Issuer (the "Board"), pursuant to which the Board determined to grant RSUs to the Reporting Person upon the achievement of certain quarterly revenue-based performance metrics. The RSUs vested on the grant date. The Company's independent board members determined that issuance of the balance of the RSUs contemplated under the Extraordinary Performance Agreement was warranted given the meaningful growth of revenue attributed to the measures and strategies employed and executed by the recipients, well beyond what was reasonably contemplated at the time the Extraordinary Performance Agreement was adopted.

The total reported in Column 5 includes the (i) 160,000 newly awarded restricted stock units, of which all 160,000 have vested (ii) 80,000 restricted stock units, of which all 80,000 have vested, (iii) 60,000 restricted stock units, of which all 60,000 have vested, (iv) 60,000 restricted stock units, of which all 60,000 have vested, (v) 75,873 restricted stock units, of which 0 have vested, (vi) 50,968 restricted stock units, of which 0 have vested, and (vii) 884 shares of common stock.


The restricted stock units (the "RSUs") granted to the Reporting Person on July 31, 2025 (the "grant date") as referenced herein, are issued pursuant to that October 31, 2024 Corporate Action, Change of Control, and Extraordinary Performance Agreement (the "Extraordinary Performance Agreement") instituted and adopted by the board of directors of the Issuer (the "Board"), pursuant to which the Board determined to grant RSUs to the Reporting Person upon the achievement of certain quarterly revenue-based performance metrics. The RSUs vested on the grant date. The Company's independent board members determined that issuance of the balance of the RSUs contemplated under the Extraordinary Performance Agreement was warranted given the meaningful growth of revenue attributed to the measures and strategies employed and executed by the recipients, well beyond what was reasonably contemplated at the time the Extraordinary Performance Agreement was adopted.

The total reported in Column 5 includes the (i) 160,000 newly awarded restricted stock units, of which all 160,000 have vested, (ii) 80,000 restricted stock units, of which all 80,000 have vested (iii) 60,000 restricted stock units, of which all 60,000 have vested, (iv) 60,000 restricted stock units, of which all 60,000 have vested, (v) 24,279 restricted stock units, of which 0 have vested, (vi) 16,310 restricted stock units, of which 0 have vested, and (vii) 169 shares of common stock.


The reported transaction involves a transfer of securities by bona fide gift for which no payment of consideration was received by the Reporting Person.

Decrease in ownership from prior Form 4s reflects the fact that shares were previously pledged by an entity controlled by the Reporting Person to secure a loan, and that such pledge is now the subject of a dispute. Based on information provided to the Reporting Person, the Reporting Person believes that the shares may have been sold prior to June 2025.


Represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of previously reported restricted stock units.


Common stock

One-fifth of the restricted stock shall vest annually on each anniversary of the July 31, 2022 vesting commencement date until fully vested on July 31, 2027.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9976 to $7.1530, inclusive. The reporting person undertakes to provide to Paysign, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Common stock


Represents a grant of 15,000 restricted stock units ("RSUs) which convert into Class A Common Stock on a one-for-one basis, pursuant to the 2022 Incentive Award Plan of the Issuer in connection with Mr. Kumar's continued service as a member of its Board of Directors as of the close of business on the date of its annual shareholder meeting. The RSUs vest in four (4) substantially equal quarterly installments on each of September 15, 2025, December 15, 2025, March 15, 2026 and June 15, 2026 as long Mr. Kumar continues to serve as a Director of the Issuer through the applicable vesting dates.

Includes 15,000 unvested RSUs.

Represents the total number of shares held after the Issuer's completion of a 1-for-10 reverse stock split that occurred on June 11, 2025.

/s/ Daniel Weinrot, Attorney-in-Fact for Tanmay Kumar


Represents a grant of 15,000 restricted stock units ("RSUs) which convert into Class A Common Stock on a one-for-one basis, pursuant to the 2022 Incentive Award Plan of the Issuer in connection with Mr. Naidu's continued service as a member of its Board of Directors as of the close of business on the date of its annual shareholder meeting. The RSUs vest in four (4) substantially equal quarterly installments on each of September 15, 2025, December 15, 2025, March 15, 2026 and June 15, 2026 as long Mr. Naidu continues to serve as a Director of the Issuer through the applicable vesting dates.

Includes 15,000 unvested RSUs.

/s/ Daniel Weinrot, Attorney-in-Fact for Taryn Naidu


CLASS A COMMON STOCK

This stock option previously vested in accordance with the terms of the applicable vesting schedule.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.29, inclusive. The reporting person undertakes to provide to Red Rock Resorts, Inc., any security holder of Red Rock Resorts, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2.

/s/ Jeffrey T. Welch, as attorney-in-fact for the Reporting Person


15,528,491 of the total reported securities are owned by Government Employees Insurance Company, a subsidiary of Berkshire Hathaway Inc. ("Berkshire"). As Berkshire is in the chain of ownership of this subsidiary, it may be deemed presently to both beneficially own and have a pecuniary interest in all shares of Common Stock presently owned by the subsidiary. Warren E. Buffett, as the controlling stockholder of Berkshire, may be deemed presently to beneficially own, but only to the extent he has a pecuniary interest in, the shares of Common Stock presently owned by the subsidiary. Mr. Buffett disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

16,632,088 of the total reported securities are owned by the following pension plans of Berkshire's subsidiaries: BNSF Master Retirement Trust (6,100,000) and Berkshire Hathaway Inc. Consolidated Pension Plan (10,532,088); each of Berkshire, Mr. Buffett and these pension plans disclaim beneficial ownership in such shares.

/s/ Warren E. Buffett, on behalf of himself and each other reporting person hereunder


These shares were issued as a restricted stock unit grant to the reporting person by the issuer.

The restricted stock units shall vest on the earlier of: (1) the day prior to the annual meeting of the shareholders of the issuer that next follows the grant date or (ii) the one-year anniversary of the grant date.


CLASS A COMMON STOCK

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.54, inclusive. The reporting person undertakes to provide to Red Rock Resorts, Inc., any security holder of Red Rock Resorts, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2.


The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.3600 to $21.3550. The Reporting Persons undertake to provide Sirius XM Holdings Inc. (formerly known as Liberty Sirius XM Holdings Inc., "Sirius XM Holdings"), any security holder of Sirius XM Holdings, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 1 to this Form 4.

108,822,227 of the total reported securities are owned as of August 4, 2025 by the following subsidiaries of Berkshire Hathaway Inc. ("Berkshire"): Government Employees Insurance Company (101,150,646), National Fire & Marine Insurance Company (1,326,491) and National Indemnity Company (6,345,090). As Berkshire is in the chain of ownership of each of these subsidiaries, it may be deemed presently to both beneficially own and have a pecuniary interest in all such shares presently owned by each of these subsidiaries. Warren E. Buffett, as the controlling stockholder of Berkshire, may be deemed presently to beneficially own, but only to the extent he has a pecuniary interest in, such shares presently owned by each such subsidiary. Mr. Buffett disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

15,984,890 of the total reported securities are owned as of August 4, 2025 by the following pension plans of Berkshire's subsidiaries: Berkshire Hathaway Consolidated Pension Plan (10,556,408), BNSF Master Retirement Trust (3,308,255), Precision CastParts Corp Master Trust (1,952,727) and Scott Fetzer Collective Investment Trust (167,500). Each of Berkshire, Mr. Buffett and these pension plans disclaims beneficial ownership in such shares.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.3600 to $21.5000. The Reporting Persons undertake to provide Sirius XM Holdings, any security holder of Sirius XM Holdings, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 4 to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.7850 to $21.2900. The Reporting Persons undertake to provide Sirius XM Holdings, any security holder of Sirius XM Holdings, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 5 to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.3100 to $21.8200. The Reporting Persons undertake to provide Sirius XM Holdings, any security holder of Sirius XM Holdings, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 6 to this Form 4.


Ordinary Shares

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer.

Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026.

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.


Ordinary Shares


Shares withheld for payment of tax liability upon vesting of the restricted stock units granted on January 6, 2023.

Shares withheld for payment of tax liability upon vesting of the restricted stock units granted on January 3, 2024.

Shares withheld for payment of tax liability upon vesting of the restricted stock units granted on January 2, 2025.


Ordinary Shares

Ordinary Shares

Ordinary Shares

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. Upon the reporting person's resignation as a director of the Issuer, effective as of immediately following the Merger Effective Time (as defined in the Transaction Agreement), each restricted unit (the "RSU") held by the reporting person automatically settled in ordinary shares of the Issuer at one share per RSU.

The number of ordinary shares withheld to satisfy tax withholding obligations arising out of the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.

Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into an RSU.

The reporting person entered into an agreement with the Issuer pursuant to which the reporting person forfeited the right to receive 9,850 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest.

The number of RSUs forfeited is based on a percentage.


Ordinary Shares

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding.

Effective at the Merger Effective Time, (i) each restricted stock unit in respect of Endo common stock ("Endo RSU") held by the reporting person immediately prior to the Merger Effective Time automatically converted into a restricted unit in respect of a number of ordinary shares of the Issuer ("Issuer RSU") determined in accordance with the formula set forth in the Transaction Agreement and (ii) each performance-based restricted stock unit in respect of Endo common stock ("Endo PSU") held by the reporting person immediately prior to the Merger Effective Time automatically converted into an Issuer RSU in respect of the number of ordinary shares of the Issuer determined in accordance with the formula set forth in the Transaction Agreement assuming the performance goals were achieved based on target performance.

The Issuer RSUs will vest ratably on April 23, 2026 and April 23, 2027. Upon vesting, each Issuer RSU will be settled in ordinary shares of the Issuer at one share per Issuer RSU.


Ordinary Shares

Ordinary Shares

Ordinary Shares


Represents a grant of 15,000 restricted stock units ("RSUs) which convert into Class A Common Stock on a one-for-one basis, pursuant to the 2022 Incentive Award Plan of the Issuer in connection with Ms. Kazerani's continued service as a member of its Board of Directors as of the close of business on the date of its annual shareholder meeting. The RSUs vest in four (4) substantially equal quarterly installments on each of September 15, 2025, December 15, 2025, March 15, 2026 and June 15, 2026 as long Ms. Kazerani continues to serve as a Director of the Issuer through the applicable vesting dates.

Includes 15,000 unvested RSUs.

Represents the total number of shares held after the Issuer's completion of a 1-for-10 reverse stock split that occurred on June 11, 2025.

/s/ Daniel Weinrot, Attorney-in-Fact for Moujan Kazerani


Represents a grant of 15,000 restricted stock units ("RSUs) which convert into Class A Common Stock on a one-for-one basis, pursuant to the 2022 Incentive Award Plan of the Issuer in connection with Mr. Civantos' continued service as a member of its Board of Directors as of the close of business on the date of its annual shareholder meeting. The RSUs vest in four (4) substantially equal quarterly installments on each of September 15, 2025, December 15, 2025, March 15, 2026 and June 15, 2026 as long Mr. Horn continues to serve as a Director of the Issuer through the applicable vesting dates.

Includes 15,000 unvested RSUs.

/s/ Daniel Weinrot, Attorney-in-Fact for John Civantos


Represents a grant of 15,000 restricted stock units ("RSUs) which convert into Class A Common Stock on a one-for-one basis, pursuant to the 2022 Incentive Award Plan of the Issuer in connection with Ms. Horn's continued service as a member of its Board of Directors as of the close of business on the date of its annual shareholder meeting. The RSUs vest in four (4) substantially equal quarterly installments on each of September 15, 2025, December 15, 2025, March 15, 2026 and June 15, 2026 as long Ms. Horn continues to serve as a Director of the Issuer through the applicable vesting dates.

Includes 15,000 unvested RSUs.

/s/ Daniel Weinrot, Attoney-in-Fact for Caroline Horn


Common Stock

The award represents the right to receive cash in an amount equal to the value of one share of the Issuers common stock on the applicable vesting date. The entire award shall vest and settle in cash on the earlier of (a) July 25, 2026, or (b) the date of the next annual meeting of the Issuers stockholders, in each case subject to the Reporting Persons continued service to the Issuer.

/s/ Cheriese Dickman as Attorney-in Fact for Monique Bonner


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Jeffrey Karbowski


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Ann Mather


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Anne M. Sweeney


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Elinor Mertz


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Susan E. Rice


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Mathias Dopfner


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Richard N. Barton


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Leslie J. Kilgore


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Strive Masiyiwa


Common Stock

By: Veronique Bourdeau, Authorized Signatory For: Bradford L. Smith


In connection with the vesting and settlement of Restricted Stock Units ("RSUs") previously granted under the Issuer's equity incentive plans, the Issuer withheld shares of
Company's Class A common stock, par value $0.000001 per share ("Class A Common Stock"), to satisfy its tax withholding obligations.

Represents the price of the Company's Class A Common Stock on the vesting date.

Includes (i) 7,622 RSUs originally granted on January 5, 2022 that vest in equal monthly installments through January 1, 2026, (ii) 221,355 RSUs originally granted on January 1, 2023 that vest in equal monthly installments through January 1, 2027, (iii) 185,328 RSUs originally granted on March 13, 2024 that vest in equal monthly installments through January 1, 2028 and (iv) 109,500 RSUs originally granted on May 21, 2025 that vest in equal monthly installments through January 1, 2029. Each RSU represents the right to receive one share of Class A Common Stock upon settlement.

/s/ James Gernetzke, attorney-in-fact for Jon Paul Richardson


Includes (i) 3,473 RSUs originally granted on January 4, 2022 that vest in equal monthly installments through January 1, 2026, (ii) 73,785 RSUs originally granted on January 1, 2023 that vest in equal monthly installments through January 1, 2027 and (iii) 61,777 RSUs originally granted on March 13, 2024 that vest in equal monthly installments through January 1, 2028. Each RSU represents the right to receive one share of Class A Common Stock upon settlement.

/s/ James Gernetzke, attorney-in-fact for Veronica McGregor


Class A Common Stock

Reflects vesting, upon certification by the Company's Compensation Committee, based on the achievement of certain stock price growth thresholds during the first of three performance periods,
which began on the date of grant and ended on the first anniversary of the date of grant.

Represents shares withheld to pay taxes applicable to vesting of RSUs.

Reflects shares of Class A Common Stock held by The Bryce Maddock Family Trust, of which the Reporting Person is the trustee.

Reflects shares of Class A Common Stock held by The Maddock 2015 Irrevocable Trust, of which the Reporting Person is the business trustee.

Reflects shares of Class A Common Stock held by The Maddock 2015 Exempt Irrevocable Trust, of which the Reporting Person is the business trustee.

Represents a grant of performance-based restricted stock units, with each restricted stock unit ("RSU")  to be settled by delivery of one share of Class A Common Stock, an equivalent amount of cash, or a combination thereof.

/s/ Scott Andreasen, as Attorney-in-Fact


These shares represent an award of restricted stock units (Total RSUs). 12.5% of the Total RSUs will vest on January 1, 2026 and 12.5% of the Total RSU will vest each date that is six (6) months thereafter until fully vested, subject to the Recipient's continued service through each applicable vest date.

Includes 1 share of common stock that was purchased on July 31, 2025 under the PDF Employee Stock Purchase Plan.

Adnan and Kanwal Raza Family Trust